SCNLF (Scancell Holdings) Other Long-Term Liabilities: $0.00 Mil (As of Oct. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCNLF Scancell Holdings PLC SCNLF
21 GF Score
Price $0.13
! 1 Warning Sign
View Full Analysis

What is Scancell Holdings Other Long-Term Liabilities?

Scancell Holdings SCNLF +4.00% 21 Other Long-Term Liabilities is $0.00 Mil as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

Scancell Holdings's other long-term liabilities for the quarter that ended in Oct. 2025 was $0.00 Mil.

Scancell Holdings's quarterly other long-term liabilities declined from Oct. 2024 ($0.00 Mil) to Apr. 2025 ($-0.00 Mil) but then increased from Apr. 2025 ($-0.00 Mil) to Oct. 2025 ($0.00 Mil).

Scancell Holdings's annual other long-term liabilities declined from Apr. 2023 ($13.57 Mil) to Apr. 2024 ($3.58 Mil) and declined from Apr. 2024 ($3.58 Mil) to Apr. 2025 ($-0.00 Mil).

Scancell Holdings Other Long-Term Liabilities Related Terms

Scancell Holdings Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Scancell Holdings's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings Other Long-Term Liabilities Chart

Scancell Holdings Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.71 12.64 13.57 3.58 -0.00

Scancell Holdings Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.13 3.58 0.00 -0.00 0.00
SCNLF
21GF Score
Scancell Holdings PLC SCNLF
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scancell Holdings Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $0.00 Mil mean?
Scancell Holdings (SCNLF) has a Other Long-Term Liabilities of $0.00 Mil as of Oct. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Scancell Holdings and its competitors.
Is Scancell Holdings' Other Long-Term Liabilities too high?
Scancell Holdings' current Other Long-Term Liabilities is $0.00 Mil. Overall, Scancell Holdings has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' Other Long-Term Liabilities compare to VRTX and REGN?
Scancell Holdings' Other Long-Term Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Scancell Holdings and its competitors. Scancell Holdings's current Other Long-Term Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current Other Long-Term Liabilities of $0.00 Mil. The current Other Long-Term Liabilities is $0.00 Mil. Scancell Holdings' overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current Other Long-Term Liabilities is $0.00 Mil as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scancell Holdings Business Description

Other Exchanges SCLP:UKSCP:Germany
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
21GF Score

Get the complete analysis for SCNLF

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price